Teva's picked an address in Parsippany, New Jersey, and the dirt's about to fly

Teva
Teva's 12-year New Jersey lease will reportedly set the company back $9 million. (Teva)

Teva now knows where it's headed in New Jersey, but it’s still got plenty of work to do before it can move into its new U.S. headquarters.

The Israeli pharma, which said earlier this month that it would move its U.S. home from Pennsylvania to the Garden State, has inked a 12-year lease for a 360,000-square-foot office building in Parsippany, NJ.com reports.

The office space won’t come cheap. The generics giant will reportedly shell out about $9 million in rent as part of a deal that “took a lot of give and take on both sides,” according to Harvey Rosenblatt, founder of the real estate developer that owns and manages the property.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The fact that Teva was already a tenant in the building, which is part of the MCC Blue office complex on Parsippany’s Interspace Parkway, helped seal the deal.

RELATED: Teva, lured by $40M tax break, packs its bags for New Jersey HQ move

On top of the hefty rent sum, Teva will be undertaking a massive construction project. “It is an astronomical build-out process,” Rosenblatt told the publication.

Thanks to an incentive package from New Jersey, though, Teva has the funds to get it done. To lure the pharma from its longtime Pennsylvania headquarters in North Wales, the state offered up $40 million in tax credits.

RELATED: What’s a move to New Jersey worth? For Teva’s U.S. headquarters, $40M in tax breaks

Teva’s move comes as the company works to consolidate sites and increase efficiency as part of its $3 billion cost-cutting drive. The plan, which will claim 14,000 jobs when all is said and done, had already affected Teva’s Pennsylvania workers before the company locked in on a relocation.

But Teva may have been weighing a switch long before it actually pulled the trigger. The company had been in touch with state officials over the last few years, and it had “various interactions” with the New Jersey Economic Development Authority from 2009 on, a public affairs director at the authority told NJ.com. The state also approved a tax credit package for Teva in early 2012, but Teva later withdrew its application.

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.